Patents Issued in February 6, 2020
  • Publication number: 20200038488
    Abstract: The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.
    Type: Application
    Filed: April 3, 2019
    Publication date: February 6, 2020
    Inventors: Elisabeth Souhami, Louise Silvestre
  • Publication number: 20200038489
    Abstract: The present invention relates to a von Willebrand factor composition for the prevention and/or the treatment of haemorrhage and/or bleeding in patients with mechanical circulatory support.
    Type: Application
    Filed: October 10, 2019
    Publication date: February 6, 2020
    Applicants: Laboratoire Francais du Fractionnement et des Biotechnologies, Ctre Hospitalier Universitaire de Lille, Universite Lille 2 Droit et Sante
    Inventors: Sophie SUSEN, Andre VINCENTELLI, Eric VAN BELLE, Antoine RAUCH, Flavien VINCENT
  • Publication number: 20200038490
    Abstract: The invention provides a blood substitute product comprising haemoglobin and a self-assembled microparticle having an acid having two or more acid groups and an organic base in a solvent. The particle is of micron scale. The microparticle may be obtained by contacting a bis-acid and organic base in a hydrophilic solvent, wherein the acid is insoluble or sparingly soluble in the hydrophilic solvent and the organic base is soluble in a hydrophilic solvent.
    Type: Application
    Filed: October 2, 2019
    Publication date: February 6, 2020
    Inventor: Donald A. Wellings
  • Publication number: 20200038491
    Abstract: The present invention provides methods of reducing liver fibrosis in a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ?1 point reduction or a ?2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration. Also provided are methods of treating a human patient with a lysosomal acid lipase (LAL) deficiency comprising administering sebelipase alfa to the patient, wherein the patient has been determined to have at least a one point reduction (e.g., a ?1 point reduction or a ?2 point reduction) in Ishak fibrosis stage after administration compared to a baseline Ishak fibrosis stage obtained from the patient prior to administration.
    Type: Application
    Filed: September 28, 2017
    Publication date: February 6, 2020
    Inventors: Anthony QUINN, Zachary GOODMAN, Barbara BURTON, Andrew RANKIN, Mark FRIEDMAN, Paresh SONI
  • Publication number: 20200038492
    Abstract: Disclosed herein are compositions and methods for use in initiating neurotoxin treatments.
    Type: Application
    Filed: April 20, 2018
    Publication date: February 6, 2020
    Inventors: Fauad Hasan, Michael Jarpe
  • Publication number: 20200038493
    Abstract: The present invention relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunomodulatory domains thereof, for use in immunotherapy. The present invention further relates to cell-penetrating effector proteins of type III secretion system (T3SS)-containing bacteria of the genus Salmonella or Shigella and variants, fragments and immunomodulatory domains thereof, for delivering cargo molecules into eukaryotic cells.
    Type: Application
    Filed: August 9, 2019
    Publication date: February 6, 2020
    Applicant: WESTFÃLISCHE WILHELMS-UNIVERSITÃT MÜNSTER
    Inventors: Marie-Luise Lubos, Alexander Schmidt, Christian Rueter
  • Publication number: 20200038494
    Abstract: Compositions include highly-concentrated Alpha-1 Proteinase Inhibitor (A1PI) in a concentration greater than or equal to 100 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions can be suitable for subcutaneous administration. The highly-concentrated A1PI solutions can be obtained by single-pass tangential flow filtration (SPTFF).
    Type: Application
    Filed: August 1, 2019
    Publication date: February 6, 2020
    Inventors: JAMES REBBEOR, CHARLES MILLER, ANTHONY KLOS, ERIC ALLGAIER, THOMAS P. ZIMMERMAN, KEVIN WEE, MICHELLE StPETER, KELLY GLANCY
  • Publication number: 20200038495
    Abstract: Compositions and methods for immunization against human breast cancer are disclosed. A breast cancer vaccine comprises an immunogenic polypeptide comprising human ?-lactalbumin.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 6, 2020
    Inventors: Vincent K. TUOHY, Justin M. JOHNSON, Ritika JAINI
  • Publication number: 20200038496
    Abstract: The present invention relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein for use in cancer immunotherapy, wherein the cancer is characterized by VEGF receptor protein expressing cancer cells. The present invention further relates to an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising an expression cassette encoding a VEGF receptor protein for use in cancer immunotherapy, wherein the cancer is characterized by VEGF receptor protein expressing cancer cells, and wherein the cancer is selected from the group consisting of glioblastoma, carcinoid cancer, kidney cancer, particularly renal cell carcinoma, thyroid cancer, lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC), breast cancer, ovarian cancer, prostate cancer, gastrointestinal cancer, particularly colorectal cancer, more particularly colon cancer, and skin cancer, particularly melanoma.
    Type: Application
    Filed: February 16, 2018
    Publication date: February 6, 2020
    Applicant: VAXIMM AG
    Inventor: Heinz Lubenau
  • Publication number: 20200038497
    Abstract: The disclosure provides various immunogens comprising a repeat unit of saccharide of Klebsiella pneumoniae CPS, which has a formula selected from the group consisting of Formulae (I) to (VI) as described herein. Also provided are vaccines including one or more immunogens selected from Formula (I) to (VI) and methods of eliciting an immune response against a Klebsiella pneumoniae and preventing infection of Klebsiella pneumoniae by using an immunogen of the invention.
    Type: Application
    Filed: October 3, 2017
    Publication date: February 6, 2020
    Applicants: NATIONAL TAIWAN UNIVERSITY, Academia Sinica
    Inventors: Jin-Town Wang, Shih-Hsiung Wu, Chung-Yi Wu
  • Publication number: 20200038498
    Abstract: The present disclosure relates to methods and compositions for treating a active tuberculosis infection and methods and compositions for improving the efficacy of chemotherapy regimens against active tuberculosis infection. The present disclosure relates to methods of treating an active M. tuberculosis infection or an active infection resulting from reactivation of a latent infection in a mammal and to methods of improving the efficacy of chemotherapy regimens against active M. tuberculosis infection.
    Type: Application
    Filed: September 10, 2018
    Publication date: February 6, 2020
    Applicant: Infectious Disease Research Institute
    Inventors: Steven G. Reed, Rhea N. Coler
  • Publication number: 20200038499
    Abstract: The disclosure relates to (i) a bacterial vaccine, comprising: at least one RNA polynucleotide having an open reading frame encoding at least one mutated bacterial antigenic polypeptide, wherein the mutated bacterial antigenic polypeptide comprises at least one asparagine (Asn) amino acid substitution; and (ii) a Streptococcal vaccine, comprising: at least one RNA polynucleotide having an open reading frame encoding at least one Streptococcal antigenic polypeptide, such as pneumolysin. Incorporating the RNA in a cationic lipid nanoparticle and a method of inducing an immune response with said vaccine are also disclosed.
    Type: Application
    Filed: March 22, 2018
    Publication date: February 6, 2020
    Applicant: ModernaTX, Inc.
    Inventors: Elisabeth Narayanan, Nadia Cohen, Giuseppe Ciaramella
  • Publication number: 20200038500
    Abstract: The present invention provides compositions, vaccines and methods for inducing protective immunity against filovirus infection, particularly protective immunity against infection of one or more subtypes of Ebola viruses and Marburg virus.
    Type: Application
    Filed: October 17, 2019
    Publication date: February 6, 2020
    Inventors: Ariane VOLKMANN, Robin STEIGERWALD, Ulrike DIRMEIER, Maria Grazia PAU, Benoit Christophe Stephan CALLENDRET, Lucy A. WARD
  • Publication number: 20200038501
    Abstract: The present invention relates to a vaccine composition comprising an effective amount of a replication-competent controlled recombinant virus. Further encompassed are uses in immunization and methods of immunization employing compositions comprising a replication-competent controlled recombinant virus of the invention.
    Type: Application
    Filed: October 24, 2019
    Publication date: February 6, 2020
    Inventor: RICHARD VOELLMY
  • Publication number: 20200038502
    Abstract: The present invention provides a vaccine composition and pharmaceutical composition for preventing or treating a viral infectious disease comprising one or more selected from the group consisting of SPOCK2 protein and a gene encoding the SPOCK2 protein as an active ingredient, a method of preparing the same, and prevention and treatment method.
    Type: Application
    Filed: September 26, 2019
    Publication date: February 6, 2020
    Inventors: Joo-Yeon YOO, Na Rae Ahn
  • Publication number: 20200038503
    Abstract: The invention provides methods for using virus-like particle (VLP) vaccines containing a stabilized pre-fusion respiratory syncytial virus (RSV) F protein to stimulate RSV neutralizing antibodies in pre-immune subjects.
    Type: Application
    Filed: September 19, 2017
    Publication date: February 6, 2020
    Inventor: Trudy G Morrison
  • Publication number: 20200038504
    Abstract: The present invention relates to a vaccine for protecting a pig against diseases associated with corona virus infection including porcine epidemic diarrhea virus (PEDV) and/or porcine deltacorona virus (PDCoV). The vaccine commonly includes inactivated/killed PEDV (e.g., chemically inactivated PED virus), and/or recombinant PEDV antigen, and/or an adjuvant inactivated/killed PDCoV (e.g., chemically inactivated PDCoV virus), and/or recombinant PDCoV antigen and an adjuvant. Methods for protecting pigs against diseases associated with PEDV and/or PDCoV and methods of producing the porcine epidemic diarrhea virus and/or porcine deltacorona virus vaccine are also provided.
    Type: Application
    Filed: January 26, 2018
    Publication date: February 6, 2020
    Inventors: Scott ACKERMAN, Joseph Ralph HERMANN, Luis Alejandro HERNANDEZ, Lea Ann HOBBS, Arun V. IYER, Sean O'CONNER, Abby Rea PATTERSON, Eric Martin VAUGHN, Joseph Gilbert VICTORIA
  • Publication number: 20200038505
    Abstract: The present invention relates to prophylactic and/or therapeutic vaccines that contain Newcastle disease Virus (NDV) virus-like particles (VLPs) comprising one or more Epstein-Barr Virus (EBV) antigens. In one embodiment, the invention provides a recombinant virus-like particle (VLP) comprising, in operable combination, a) Newcastle disease virus (NDV) matrix (M) protein, and b) one or more Epstein-Barr Virus (BBV) antigens. The invention's prophylactic and/or therapeutic vaccines are useful for preventing and/or treating infection with EBV and/or disease associated Epstein-Barr Virus, such as cancer.
    Type: Application
    Filed: April 19, 2019
    Publication date: February 6, 2020
    Inventors: Javier Gordon Ogembo, Trudy Morrison
  • Publication number: 20200038506
    Abstract: The present invention provides methods for the treatment of a subject having a Hepatitis B virus (HBV) infection, e.g., a chronic HBV infection, using a combination of an RNAi agent that targets HBV and an HBV vaccine. It is disclosed a RNAi agent and an HBV vaccine for use in treatment of HBV infection, comprising sequentially administering to the subject having an HBV infection: a) an RNAi agent that inhibits expression of at least three HBV transcripts, wherein the RNAi agent forms a double stranded region; b) a protein-based vaccine comprising a first HBV core antigen (HBcAg) polypeptide, and a first HBV surface antigen (HBsAg) polypeptide; and c) a nucleic acid-based vaccine comprising an expression vector construct encoding a second HBcAg polypeptide, and/or a second HBsAg polypeptide, wherein the second HBcAg polypeptide, and/or the second HBsAg polypeptide, shares at least one epitope with at least one of the first HBcAg polypeptide, and/or the first HBsAg polypeptide.
    Type: Application
    Filed: April 18, 2018
    Publication date: February 6, 2020
    Inventors: Laura Sepp-Lorenzino, Ulrike Protzer, Thomas Michler
  • Publication number: 20200038507
    Abstract: A method for delivering allergens to a pharmacist in a pre-diluted kit form, comprising providing a bulk container of base concentrate antigen containing at least one antigen at a predetermined concentrated level, creating a sequential and more diluted sequence of antigens, providing a plurality of end-use sealable containers that can receive a finite end amount of diluted antigens, dispensing from each of sequential bulk containers a finite end amount of diluted antigens into one of the plurality of end-use sealable containers, wherein the end-use seal containers filled from each of the sequential bulk containers comprises a group of end-use sealable containers associated with each of the sequential bulk containers, sealing each of the end-use containers after diluted antigens are disposed therein, and disposing a select number of the sealed end-use sealable containers from each of the groups of end-use sealable containers into a container comprising a kit.
    Type: Application
    Filed: October 16, 2019
    Publication date: February 6, 2020
    Inventors: James STRADER, Jovan PULITZER
  • Publication number: 20200038508
    Abstract: The present invention provides a medicine comprising a Toll-like receptor agonist, LAG-3 protein, a variant or derivative thereof.
    Type: Application
    Filed: April 14, 2017
    Publication date: February 6, 2020
    Applicant: CYTLIMIC INC.
    Inventors: Tomoya MIYAKAWA, Shun DOI, Koji TAMADA
  • Publication number: 20200038509
    Abstract: Embodiments of the disclosure concern methods and compositions for treating cancer in an individual that includes combination therapy comprising radiofrequency therapy and immunotherapy. In specific embodiments, utilization of the radiofrequency therapy invokes the immune system of the individual to provide an environment at the tumor that is receptive to native immune system components of the individual, and/or exogenously provided immune system components. In specific cases, the radiofrequency therapy enhances T cell localization to the tumor.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 6, 2020
    Inventors: Stuart James Corr, Jared M. Newton, Steven A. Curley, Andrew G. Sikora
  • Publication number: 20200038510
    Abstract: Described here is a method for reducing or preventing Pseudomonas aeruginosa biofilm formation in a human subject in need thereof, comprising administering to the human subject a first composition comprising (a) an antigen-binding polypeptide that binds Pf-family bacteriophage, or (b) a vaccine against Pf-family bacteriophage. Also described is an antigen-binding polypeptide that binds specifically to a CoaB protein of Pf-family bacteriophage or fragment thereof.
    Type: Application
    Filed: January 30, 2019
    Publication date: February 6, 2020
    Inventors: Paul L. Bollyky, William Parks, Patrick Secor
  • Publication number: 20200038511
    Abstract: Methods and compositions related to the engineering of a protein with L-cyst(e)ine degrading enzyme activity are described. For example, in certain aspects there may be disclosed a modified cystathionine-?-lyase comprising one or more amino acid substitutions and capable of degrading L-cyst(e)ine. Furthermore, certain aspects of the invention provide compositions and methods for the treatment of cancer with L-cyst(e)ine using the disclosed proteins or nucleic acids.
    Type: Application
    Filed: June 13, 2019
    Publication date: February 6, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventors: George GEORGIOU, Everett STONE
  • Publication number: 20200038512
    Abstract: Methods and composition for cell-based therapy as well as somatostatin receptor-based therapy are described. For example, in certain aspects methods for administering an anti-tumor therapy using a signaling defective somatostatin receptor mutant are described. Furthermore, the invention provides compositions and methods involve a somatostatin constitutively active somatostatin receptor mutant.
    Type: Application
    Filed: October 22, 2019
    Publication date: February 6, 2020
    Applicant: Board of Regents, The University of Texas System
    Inventor: Vikas KUNDRA
  • Publication number: 20200038513
    Abstract: The present disclosure relates to bifunctional compounds, which find utility as modulators of focal adhesion kinase (FAK) or protein tyrosine kinase 2 (PTK2). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    Type: Application
    Filed: July 26, 2019
    Publication date: February 6, 2020
    Inventors: Craig M. Crews, Philipp M. Cromm, Andrew P. Crew
  • Publication number: 20200038514
    Abstract: Methods are provided for treating cancers using a conjugate herein described as Conjugate 5, or a pharmaceutically acceptable salt thereof. Methods for treating cancers using Conjugate 5, or a pharmaceutically acceptable salt thereof, to target tumor associated macrophages are also described.
    Type: Application
    Filed: September 14, 2017
    Publication date: February 6, 2020
    Inventors: Iontcho Radoslavov VLAHOV, Christopher Paul LEAMON, Longwu QI, Ning ZOU, Kevin Yu WANG, Albert E. FELTEN, Garth L. PARHAM, Fei YOU, Hari Krishna R. SANTHAPURAM, Spencer J. HAHN, Joseph Anand REDDY, Yingjuan J. LU, Leroy W. WHEELER, II
  • Publication number: 20200038515
    Abstract: The present invention provides, among other things, compositions and methods of formulating nucleic acid-containing nanoparticles comprising no more than three distinct lipids components, one distinct lipid component being a sterol-based cationic lipid. In some embodiments, the present invention provides compositions and methods in which the lipid nanoparticles further comprise helper lipids and PEG-modified lipids. The resulting formulation comprises a high encapsulation percentage for nucleic acids.
    Type: Application
    Filed: October 11, 2019
    Publication date: February 6, 2020
    Inventors: Frank DeRosa, Michael Heartlein, Shrirang Karve
  • Publication number: 20200038516
    Abstract: In some aspects, the present invention provides cell-reactive compstatin analogs and compositions comprising cell-reactive compstatin analogs. In some aspects, the invention further provides methods of using cell-reactive compstatin analogs, e.g., treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides long-acting compstatin analogs and compositions comprising long-acting compstatin analogs. In some aspects, the invention further provides methods of using long-acting compstatin analogs, e.g., to treat a complement-mediated disorder, e.g., to inhibit complement-mediated damage to a cell, tissue, or organ. In some aspects, the invention provides targeted compstatin analogs and compositions comprising targeted compstatin analogs. In some aspects, the invention further provides methods of using targeted compstatin analogs, e.g., to treat a complement-mediated disorder, e.g.
    Type: Application
    Filed: April 9, 2018
    Publication date: February 6, 2020
    Inventors: Federico Grossi, Pascal Deschatelets, Cedric Francois, Patrick Johnson, Carolina Vega
  • Publication number: 20200038517
    Abstract: The invention relates to (among other things) oligomer-phenothiazine conjugates and related compounds. A conjugate of the invention, when administered by any of a number of administration routes, exhibits advantages over un-conjugated phenothiazine compounds.
    Type: Application
    Filed: October 11, 2019
    Publication date: February 6, 2020
    Inventors: Xuyuan Gu, Jennifer Riggs-Sauthier
  • Publication number: 20200038518
    Abstract: A mitochondrial-targeted PARP inhibitor is provided herein, as well as methods of making and using the mitochondrial-targeted PARP inhibitor.
    Type: Application
    Filed: October 13, 2017
    Publication date: February 6, 2020
    Inventors: Hulya Bayir, Robert Clark, Tanja Krainz, Peter Wipf
  • Publication number: 20200038519
    Abstract: The present application relates to an immunostimulatory compound comprising an immunostimulant portion and a peptide portion. The peptide portion is not a disease-associated immunogen. Furthermore, the peptide portion has an amino acid sequence in which 75% or less of the amino acid residues are hydrophobic and/or has an isoelectric point of 5 or greater. The compounds of the invention address the problem of systemic distribution of immunostimulants causing unwanted side effects. The inventors have found that the physicochemical properties of the immunostimulant can be controlled by covalent linkage to a peptide. Further physicochemical properties may be modified in a useful manner by incorporating additional features.
    Type: Application
    Filed: October 7, 2019
    Publication date: February 6, 2020
    Inventor: Bertrand GEORGES
  • Publication number: 20200038520
    Abstract: The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular DNA near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-DNA so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide.
    Type: Application
    Filed: August 19, 2019
    Publication date: February 6, 2020
    Inventors: RICHARD H. WEISBART, Robert N. Nishimura
  • Publication number: 20200038521
    Abstract: The present invention provides isolated nucleic acid compounds, amino acids compounds and related materials, along with methods to make and use the compounds. In particular, there are provided gene therapy materials useful for inducing positive physiological responses in tissues, and fusion proteins encoded by the gene therapy materials.
    Type: Application
    Filed: October 7, 2019
    Publication date: February 6, 2020
    Inventors: Stephen B. Trippel, Shuiliang Shi
  • Publication number: 20200038522
    Abstract: Described are nucleic acid regulatory elements that are able to enhance liver-specific expression of genes, methods employing these regulatory elements and uses of these elements. Expression cassettes and vectors containing these nucleic acid regulatory elements are also disclosed. These are particularly useful for applications using gene therapy.
    Type: Application
    Filed: October 21, 2019
    Publication date: February 6, 2020
    Inventors: Marinee Chuah, Thierry Vandendriessche, Pieter De Bleser
  • Publication number: 20200038523
    Abstract: The present invention relates to a prostate-specific membrane antigen (PSMA)-specific binding protein, wherein the PSMA-specific binding protein is a lipocalin 2 (Lcn2)-derived binding protein and binds to PSMA with a KD of 10 nM or lower. The present invention also relates to a nucleic acid molecule encoding the PSMA-specific binding protein of the invention, a vector comprising said nucleic acid molecule of the invention and a host cell transformed with the vector. Furthermore, the invention relates to a method of producing the PSMA-specific binding protein of the invention, the method comprising culturing the host cell of the invention under suitable conditions and isolating the PSMA-specific binding protein produced. The present invention further relates to a protein conjugate comprising the PSMA-specific binding protein of the invention, or the PSMA-specific binding protein produced by the method of the invention.
    Type: Application
    Filed: July 17, 2019
    Publication date: February 6, 2020
    Applicants: TECHNISCHE UNIVERSITÄT MÜNCHEN, BIOTECHNOLOGICKY USTAV AV CR, V.V. I.
    Inventors: Arne Skerra, Antonia Richter, Volker Morath, Cyril Barinka, Jakub Ptacek
  • Publication number: 20200038524
    Abstract: Activity-based probe compounds for use in labeling a cysteine protease are provided. The compounds are targeted to the protease through a specific targeting element. The compounds additionally include a detectable element, such as a fluorescent label, a radiolabel, or a chelator. In some cases, the compounds additionally include a quenching element that is released upon reaction with the protease. Also provided are compositions comprising the compounds and methods for using the compounds, for example in labeling a protease in an animal and in visualizing a tumor in an animal.
    Type: Application
    Filed: December 23, 2017
    Publication date: February 6, 2020
    Inventors: Matthew S. BOGYO, Martijn VERDOES
  • Publication number: 20200038525
    Abstract: Silica nanocarriers hybridized with superparamagnetic iron oxide nanoparticles (“SPIONs”) and curcumin through equilibrium or enforced adsorption technique. Methods for dual delivery of SPIONs and curcumin to a target for diagnosis or therapy, for example, for SPION-based magnetic resonance imaging or for targeted delivery of curcumin to a cell or tissue. The technique can be extend to co-precipitation of mixed metal oxide involving Ni, Mn, Co and Cu oxide. The calcination temperature can be varied from 500-900° C. The nanocombination is functionalized with chitosan, polyacrylic acid, PLGA or another agent to increase its biocompatibility in vivo.
    Type: Application
    Filed: August 6, 2018
    Publication date: February 6, 2020
    Applicant: Imam Abdulrahman Bin Faisal University
    Inventors: B. Rabindran JERMY, Vijaya RAVINAYAGAM
  • Publication number: 20200038526
    Abstract: It is described a composition comprising lyophilized rhAnnexin V-128 suitable for the preparation of 99mTc-rhAnnexin V-128 formulations suitable for intravenous administration.
    Type: Application
    Filed: October 11, 2017
    Publication date: February 6, 2020
    Applicant: Advanced Accelerator Applications International S.A.
    Inventors: Lorenza Fugazza, Maurizio Franco Mariani, Francesca Orlandi, Daniela Chicco, Donato Barbato
  • Publication number: 20200038527
    Abstract: Disclosed are chelates resulting from the complexation of bifunctional do2pa derivatives ligands of formula (I), wherein the substituents R1, R1?, R2, R2?, R3, R3?, L1, L1?, L2 and L2? are defined as in the claims, with metallic cations, especially Pb(II) and Bi(III). Also disclosed are bifunctional do2pa derivatives ligands of formula (I), as well as the use of chelates in nuclear medicine and the use of ligands in cations detection or epuration of effluents.
    Type: Application
    Filed: September 23, 2019
    Publication date: February 6, 2020
    Inventors: Fatima OUKHATAR, Maryline BEYLER, Raphaël TRIPIER
  • Publication number: 20200038528
    Abstract: The invention relates to a radiolabelled material comprising a polymer, a radioactive isotope, and an immobilizing agent, wherein the immobilizing agent is capable of immobilizing the radioactive isotope on or in the polymer, and wherein the immobilizing agent is a macromolecule comprising a polycation with multiple pendant metal-chelating side-chains. The invention also relates to a process for making a radiolabelled material, to use of a radiolabelled material for the preparation of medicaments for treating cancer and/or for radiation imaging and to use of a radiolabelled material in the treatment of cancer. There is further described use of an immobilizing agent to immobilize a radioactive isotope on or in a polymer.
    Type: Application
    Filed: December 15, 2017
    Publication date: February 6, 2020
    Inventors: Ross Wentworth Stephens, Gregory David Tredwell, Karen Joanne Knox, Lee Andrew Philip, Rebecca Greenlees, Keira Beattie
  • Publication number: 20200038529
    Abstract: Methods for sterilizing a substrate with radiation and radiation sterilized substrates.
    Type: Application
    Filed: January 19, 2018
    Publication date: February 6, 2020
    Inventors: David J. Farrell, John P. O'Mahony
  • Publication number: 20200038530
    Abstract: A cold plasma system and method for treating a region of a biological surface is presented. In one embodiment, the system includes: a housing; an air conduit within the housing; a first electrode configured proximately along the air conduit; a second electrode configured proximately along the air conduit and opposite from the first electrode; and a source of alternating current (AC) electrically connected with the first electrode. The source of alternating current is configured to generate cold plasma in the air conduit.
    Type: Application
    Filed: July 30, 2019
    Publication date: February 6, 2020
    Applicant: L'Oreal
    Inventors: Ozgur Emek Yildirim, Thi Hong Lien Planard-Luong, Matthieu Jacob, Geoffrey Deane
  • Publication number: 20200038531
    Abstract: A unitary, single-use, sanitary sterilizing wipe for a beverage can. It has a number of can wiping interfaces incorporated into its design that matingly conforms to a standard beverage can, and uses a natural sterilizing fluid that is frictionally wiped onto the can's outer surfaces before drinking from the can. It may be used anywhere by opening the polymer seal, removing the wipe, placing it on the top of a beverage can and twisting it under pressure to sterilize the can.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventor: Michael McGrade
  • Publication number: 20200038532
    Abstract: There is provided a method and apparatus for operating a sterilization chamber such that one version of Programmable Logic Controller (PLC) software is compatible with any number of hardware configurations of the sterilization chamber. The PLC software is divided into a core module for operations which are the same across all hardware configurations, and a template module for hardware specific operations. Configuration data, state data, and live data are segregated from each other.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 6, 2020
    Inventors: Peter VESELOVSKY, Michael OMATSU, Ahmad JUQQA, Nader Hijazi
  • Publication number: 20200038533
    Abstract: There is provided a method and apparatus for operating a sterilization chamber such that one version of Programmable Logic Controller (PLC) software is compatible with any number of hardware configurations of the sterilization chamber. The PLC software is divided into a core module for operations which are the same across all hardware configurations, and a template module for hardware specific operations. Configuration data, state data, and live data are segregated from each other.
    Type: Application
    Filed: October 9, 2019
    Publication date: February 6, 2020
    Inventors: Peter VESELOVSKY, Michael OMATSU, Ahmad JUQQA, Nader Hijazi
  • Publication number: 20200038534
    Abstract: A method of sterilizing medical instruments using a vacuum chamber connected to reservoir by a valve in a closed state is disclosed that includes placing instruments in a non-sterile state into a sterilization pack, opening a chamber, placing the pack into the chamber, closing the chamber, withdrawing a first volume of air from the chamber, changing a volume of liquid water into vapor, opening the valve, introducing sterilant into the chamber, introducing a second volume of air into the chamber, opening the chamber, removing the pack from the chamber, and removing the instruments in a sterile-state from the pack. The process may further include the steps of repeatedly determining pressure within the chamber, calculating second-derivative values of pressure with respect to time, and determining whether any local maxima exist in a plot of second derivative values that correspond to pressures above and/or below the triple-point pressure of water.
    Type: Application
    Filed: October 14, 2019
    Publication date: February 6, 2020
    Inventors: Doug Vo TROUNG, Todd MORRISON
  • Publication number: 20200038535
    Abstract: Method for sterilizing a hydrophilically coated medical device.
    Type: Application
    Filed: January 18, 2018
    Publication date: February 6, 2020
    Inventors: Horacio Montes De Oca, Jerome A. Henry, Shamsedin Rostami
  • Publication number: 20200038536
    Abstract: A device for generating and dispersing chlorine dioxide which includes a housing, at least one removeable tray having a plurality of compartments contained within an interior of the housing, and a fan in communication with the interior of the housing and the exterior of the housing for directing a current of chlorine dioxide gas that is generated from chemicals that are positioned within the removeable tray(s).
    Type: Application
    Filed: October 7, 2019
    Publication date: February 6, 2020
    Inventor: Kenneth Horvath
  • Publication number: 20200038537
    Abstract: The present invention relates to freshening compositions, devices comprising same and methods of using same for freshening the atmosphere, the air or surfaces. Also provided are methods for manufacturing the freshening compositions and devices comprising same. Disclosed are non-glycol ether liquid freshening compositions comprising a fragrance release modulator. A freshening composition of this invention may comprise (i) from about 0.1 wt % to about 95 wt % perfume raw materials, (ii) from about 0.01 wt % to about 90 wt % fragrance release modulator, and (iii) from about 1.0 wt % to about 95 wt % solvents, diluents or a mixture thereof. Disclosed are passive and active air or surface freshening products comprising a freshening composition of the present invention that allow controlled and customized release of the freshening composition to the atmosphere, air, or onto surfaces.
    Type: Application
    Filed: July 29, 2019
    Publication date: February 6, 2020
    Inventors: Florin-Iosif Vlad, Austin Howard